Marsha A. Raebel, PharmD

Senior Investigator

Marsha RaebelMarsha A. Raebel, PharmD, is Senior Investigator at the Institute for Health Research. Her research focuses on patient safety, medication adherence, and pharmacoepidemiology, with an emphasis on adverse drug event surveillance and reducing medication and laboratory monitoring errors in the outpatient setting.

Dr. Raebel completed her doctoral training in pharmacotherapy at the University of Texas at Austin Health Sciences Center. She is nationally-recognized for her foundational research in medication adherence and safety, diabetes, clinical pharmacy, and clinical decision support. She is the coordinating investigator across Kaiser Permanente for the U.S. Food and Drug Administration (FDA) Sentinel initiative and an investigator in the FDA-sponsored Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) project.

Dr. Raebel is a Clinical Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and a member of the American College of Clinical Pharmacy.


Selected Research

  • Privacy-Preserving Analytic and Stat-Sharing Methods for Clinical and Patient-Powered Data Networks

    The project will 1) increase the understanding and utility of privacy-preserving methods in multi-center patient-centered outcomes research (PCOR) studies, 2) Develop a suite of flexible analytic and data-sharing methods to handle a wide range of stakeholder needs, preferences, and priorities in multi-center PCOR studies, and 3) Improve the efficiency of multi-site PCOR studies by reducing barriers to data sharing.
    Funder: Patient-Centered Outcomes Research Institute
    Study End Date: 12/31/2017

  • Support Workgroup Activities for Task Order 7 (The Potential Exposure/Outcome Associations)
    Funder: U.S. Food & Drug Administration
    Study End Date: 12/31/2017
  • M-S Support Workgroup Activities for Task Order 12
    Funder: U.S. Food & Drug Administration
    Study End Date: 3/5/2018

  • Using a Medical Data Warehouse to assess Laboratory Quality Improvement Outcomes
    The purpose of this study is to demonstrate how healthcare data in a MDW enables evaluation of a laboratory medicine QI initiative. Outcomes are: Raised awareness 1) that MDWs can be used to identify & address laboratory quality gaps and 2) of a specific QI intervention to improve patient and/or system outcomes.
    Funder: Centers for Disease Control & Prevention
    Study End Date: 8/31/2019
  • Evaluation of the Risk of Neural Tube Defects Among Live Births Exposed to Maternal Prescription Opioids During Early Pregnancy
    The goal of this study is to study the association between opioid use during early gestation and primary neural tube defects.
    Funder: U.S. Food & Drug Administration
    Study End Date: 9/28/2019
  • FibeOric Liver Disease (Fold) Consortium
    Funder: Henry Ford Health System
    Study End Date: 3/31/2020
  • The Breathewell Program to Improve Asthma Outcomes

    The goal of this study is to further our understanding of how to leverage EHRs to improve guidelines-concordant asthma care in routine practice.
    Funder: National Heart, Lung, & Blood Institute
    Study End Date: 8/31/2020

  • Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP)
    Funder: U.S. Food & Drug Administration
    Study End Date: 9/14/2021